Axogen Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 26.6% year-over-year to $61.5M in Q1 2026, with strong double-digit growth across all markets and expanded commercial coverage. Full-year guidance was raised to at least $270M revenue and 74%-76% gross margin, with continued investment in sales force and innovation.
-
Achieved broad BLA label and 12 years of exclusivity, enabling continued market leadership in nerve care. Insurance coverage is expanding, with all technical requirements met for major payers, and CMS reimbursement has improved. Growth strategies focus on education, targeted accounts, and expanding the sales force.
-
Validated business models and double-digit growth across all segments are driving expansion, with a strengthened balance sheet and at least 18% top-line growth targeted for 2026. Regulatory milestones and reimbursement wins set the stage for operational efficiencies and broader market access.
-
Focused on making peripheral nerve restoration a standard of care, the company targets growth in extremities, breast, and oral maxillofacial markets, with prostate care in development. Recent BLA approval for AVANCE supports payer coverage and operational improvements, while strong financials and a recent capital raise position the company for continued expansion.
-
The presentation highlighted a clear strategic focus on expanding peripheral nerve care, leveraging the recent BLA approval for Avance to drive growth, improve margins, and enhance reimbursement. High double-digit growth is expected in elective markets, with new clinical pathways and international expansion under evaluation.
Fiscal Year 2025
-
Revenue grew 20% year-over-year with strong double-digit growth across all markets and a key FDA BLA approval for Avance. 2026 guidance targets at least 18% revenue growth, with gross margin stability and continued investment in commercial and R&D initiatives.
-
A leading innovator in nerve repair aims to set new standards of care with unique allograft products and a robust clinical portfolio, targeting 15%-20% annual growth and global expansion. Recent reimbursement improvements and strong clinical evidence support continued adoption.
-
The session highlighted a strong growth outlook driven by expanding clinical guidelines, payer coverage, and a stratified salesforce. BLA approval is expected by December 5, unlocking operational efficiencies and reinforcing market leadership. Gross margins are projected to remain above 75%.
-
Q3 2025 saw 23.5% revenue growth, strong gross margin, and net income improvement, driven by Avance Nerve Graft adoption and expanded payer coverage. BLA approval for Avance is expected by December, securing market exclusivity and supporting further growth.
-
Q2 2025 revenue grew 18.3% year-over-year to $56.7 million, driven by strong adoption across all target markets and high-potential accounts. Gross margin improved to 74.2%, and full-year revenue guidance was raised to at least 17% growth, with BLA approval for Avance Nerve Graft on track for September.
-
The event outlined a strategic plan focused on expanding clinical applications, international growth, and ongoing product innovation, with guidance for 15%-20% growth over the next four to five years. Positive cash flow and a strong benefit-risk profile support continued investment and market expansion.
-
Q1 2025 revenue rose 17.4% year-over-year to $48.6M, with double-digit growth in all markets and strong execution in key accounts. Gross margin fell to 71.9% due to higher costs and inventory write-offs, but full-year guidance is unchanged. BLA approval for Avance Nerve Graft is on track for September, securing 12 years of exclusivity.
-
A 15–20% CAGR is targeted through 2028, with expansion in core and new markets, including prostate and international. Standard of care status, coverage expansion, and innovation are key drivers, supported by strong clinical evidence and operational cash flow growth.
Fiscal Year 2024
-
Full year 2024 revenue grew 17.8% to $187.3M, with Q4 up 15.1% year-over-year and strong gross margin improvement. A new strategic plan targets a $5B TAM and 15%-20% CAGR, with 2025 revenue growth expected at 15%-17% and continued cash flow positivity.
-
Q3 2024 saw 17.9% revenue growth and improved profitability, driven by broad-based portfolio gains and operational efficiencies. The FDA accepted the BLA for Avance Nerve Graft, setting up potential market exclusivity, while full-year guidance and positive cash flow outlook were reaffirmed.
-
Q2 2024 saw 25.6% revenue growth, improved adjusted EBITDA, and strong sales productivity. Guidance was raised for the year, with continued margin pressure from new facility costs but expectations for improvement. Leadership transition and new product launches support future growth.